LAG3 Expression in Triple Negative Breast Cancer

Recruiting now · Not applicable

Conditions studied: Triple Negative Breast Cancer, Immune Checkpoint Inhibitor

In brief

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Key facts

Study ID

NCT06259162

Run by

Samsung Medical Center

People needed

128

Starts

2022-11-18

Expected to finish

2027-12-31

Last updated by the study team

2024-02-14

Who can join

Age: any. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Planned neoadjuvant chemotherapy
• Triple negative breast cancer

You may not qualify if…

• HER2-positive breast cancer
• Hormone receptor positive breast cancer

Where it is running

• Ji-Yeon Kim — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.